Eton Pharmaceuticals Launches FDA-Approved Galzin for Wilson Disease Maintenance Treatment
Key Insights
Eton Pharmaceuticals (search) has launched Galzin (zinc acetate) capsules, the only FDA-approved zinc therapy for Wilson disease (search) maintenance treatment, offering improved access through their specialty pharmacy network.
The company introduces the Eton Cares Program, providing $0 co-pay for eligible patients and comprehensive support services, addressing historic availability and affordability challenges.
Through partnership with Optime Care (search) specialty pharmacy, Eton aims to enhance treatment accessibility while investing in research for advancing Wilson disease (search) therapeutics.
Eton Pharmaceuticals (search) (Nasdaq: ETON) has initiated the commercial launch of Galzin® (zinc acetate) capsules, marking a significant development in the treatment landscape for Wilson disease (search). The FDA-approved maintenance therapy addresses a critical need for patients who have previously undergone chelation therapy.
Expanding Access to Critical Treatment
The launch represents a strategic move to improve treatment accessibility for Wilson disease (search) patients, many of whom have historically relied on unapproved compounded products or over-the-counter supplements. Sean Brynjelsen, CEO of Eton Pharmaceuticals (search), emphasized the company's commitment to patient care: "We are dedicated to increasing both access to and awareness of this critical medication. Through Eton Cares, we intend to ensure that every patient that needs Galzin will have access to it."
Comprehensive Patient Support Initiative
The Eton Cares Program, administered through Optime Care (search) specialty pharmacy, offers:
- $0 co-pay for eligible patients
- Prescription fulfillment services
- Insurance benefits investigation
- Educational support
- Financial assistance for qualified patients
"Galzin is an important medication for Wilson disease (search) patients, and we look forward to partnering with Eton to ensure patients have continued access to this drug," stated Rhonda Rowland, President of the Wilson Disease Association (search).
Clinical Considerations and Safety Profile
Healthcare providers should note several important clinical considerations when prescribing Galzin:
- Administration should occur on an empty stomach, at least one hour before or two to three hours after meals
- Regular monitoring of patients through assessment of Wilson's disease signs and symptoms
- 24-hour urine copper measurements are essential for treatment monitoring
- Neuropsychiatric evaluations and liver function tests should be conducted as appropriate
The safety profile includes important warnings about potential copper deficiency with extended use and the risk of gastric ulcers. Healthcare providers should monitor for complications such as anemia, various cytopenias, and myeloneuropathy.
Research and Development Commitment
Eton Pharmaceuticals (search) has signaled its long-term commitment to the Wilson disease (search) community by actively investing in research and development efforts. This investment aims to drive meaningful advancements in treatment options and patient outcomes.
Healthcare professionals can initiate Galzin prescriptions through e-prescribing via Optime Care (search) or by faxing patient referral forms. Detailed product information is available through the dedicated website, www.galzin.com.